Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon

Recaps

I Can Extract Side Effects
VolumesArcsSummaries

Vol. 3Sanqing Goes Global

Wei Kang expanded Sanqing’s medicines, gene-editing work, and agricultural products while overcoming patent disputes and building international partnerships. After growing Sanqing’s formula collection to more than two thousand prescriptions, he used the system’s drawing function and won a blueprint for an electronic product.

  • Wei Kang responded to Illumina’s sequencer cutoff by testing domestic machines and expanding Sanqing’s drug projects, while its scar-removal cream became a major success.
  • Sanqing’s scar-removal cream sold out, and reports revealed that locusts had returned to Feizhou in overwhelming numbers.
  • Xia Lizhi and foreign officials used Sanqing’s pesticide to kill locusts, bringing the company major international orders.
  • Sanqing developed a Thalassemia Gene Drug for Salman and advanced Super Soybean trials, with one variety yielding more than 1,000 jin per mu.
  • Wei Kang and Tang Que developed a new gene-editing technology as Sanqing faced patent lawsuits and a halt to its Eagle Country sales, before the Broad Institute withdrew its suit.
  • Wang De arranged Super Soybean deals abroad, while Zhang Chunming shifted Sanqing’s Feizhou medicine strategy toward local partnerships and aid.
  • Wei Kang expanded Three Purities’ overseas charity and launched safer cardiovascular drugs as Sanofi recalled contaminated Irbesartan and Sanqing’s business grew.
  • Wei Kang acquired abandoned drug formulas, collected more than two thousand prescriptions, and won an electronic-product blueprint through system draws.
Chapters 201–300 Read from Ch. 201

Arc 9New Medicines and New Threats

Wei Kang responded to Illumina’s supply cutoff by testing domestic gene sequencers and expanded Sanqing’s drug development into cardiovascular, pet, and beauty medicines. The scar-removal cream became a major success, but a report of a massive locust return left the story facing a new threat.

  • Jian Lianyun cooked dinner at Wei Kang’s villa and stayed overnight, while Wei Kang learned that Illumina had delayed Three Purities’ Gene Sequencers and suspected a coordinated cutoff.
  • Wei Kang ordered domestic sequencers from Daxia Intelligent Manufacturing and Carbon Base, and Three Purities tested their machines as Daxia improved its technology and expanded sales.
  • Wei Kang selected seven useful side effects from abandoned prescriptions and assigned new drug projects to his researchers, including treatments for high blood pressure, blood clots, allergies, and feline infectious peritonitis.
  • Chen Yiqing tested Sanqing’s FIP antiviral at Xinchen Pet Hospital, where treated cats improved, and Magical Girl’s Snowflake recovered after taking the medicine.
  • After In the Water was arrested for selling counterfeit drugs, Wei Kang announced Sanqing’s entry into pet medicine and established an Animal Protection department.
  • Sanqing employees tested scar-removal and hair-removal creams, and Yang Li and Zhang Qiqi helped promote the scar cream after their scars faded or disappeared.
  • Xu Bo used Sanqing’s scar-removal ointment to recover from severe burns and return to the fire station, helping draw widespread attention to the product.
  • Sanqing’s scar-removal cream sold out after launch, while a news report announced that Feizhou locusts had returned in numbers twenty times greater than before.
Chapters 201–22525 summaries Read

Arc 10Sanqing’s Expanding Reach

Sanqing Pharmaceutical’s fast-acting locust pesticide brought the company international attention, while its medicines helped patients and its gene-editing work advanced in healthcare and agriculture. The arc ended with high-yield Super Soybeans and other improved crops entering wider trials.

  • Chinese agricultural officials tested Sanqing’s low-toxicity pesticide, and Xia Lizhi used it to kill locusts in Pakistan within minutes.
  • Ethiopian officials chose Three Purities’ insecticide after seeing its success, and countries across the affected regions placed large orders through Syngenta.
  • Sun Chengren and Gu Xian negotiated medicine sales in Africa, while Salman brought Thalassemia patients to China and Sanqing began developing a tailored Gene Drug.
  • Wang De and Three Purities formed a partnership to develop gene-edited crops, producing soybean samples that Syngenta planted for trials.
  • Sanqing’s experimental cardiovascular drugs helped Song Zhi Xing recover from paralysis, and his reunion with wartime comrades followed.
  • Sanqing developed a Thalassemia Gene Drug that restored Salman’s health, then launched a charity foundation to fund treatment trials for other patients.
  • Brother Jiazhen exposed weaknesses in other fundraising platforms and showed that Sanqing’s Longtu APP checked applicants’ eligibility before approving aid.
  • Wang De’s team measured Super Soybean yields above 1,000 jin per mu for one variety and prepared wider trials of the soybeans and other improved crops.
Chapters 226–25025 summaries Read

Arc 11The Gene Patent War

Wei Kang and Sanqing faced patent lawsuits and a blocked Eagle Country market while developing a new gene-editing technology. The conflict eased as the Broad Institute withdrew its suit, and Syngenta expanded Super Soybean sales abroad while Sanqing shifted its Feizhou drug strategy toward local partnerships and aid.

  • Consumers rushed to buy domestic cooking oil after Super Soybean’s record yield drew attention, and Wei Kang praised General Manager Wang’s publicity campaign.
  • Wei Kang tasked Tang Que with finding an independent gene-editing tool, and Three Purities’ Gene Laboratory began working with the China Academy of Sciences.
  • Zheng Feng and Wei Kang settled the Broad Institute’s first patent dispute by agreeing that Sanqing would pay 25% of profits on each Thalassemia Gene Drug sold.
  • After the Broad Institute filed suit and the FDA halted Sanqing’s Eagle Country sales, Tang Que revealed a new protease from an ancient Antarctic bacterium and a promising upgraded gene drug.
  • Zheng Feng joined forces with Dr. Dudna to revoke Sanqing’s CRISPR licenses, but Three Purities won the Chinese jurisdiction dispute and the Broad Institute later withdrew its lawsuit.
  • Wang De secured a Tanzanian agreement for farmers to grow Super Soybeans for guaranteed purchase, then negotiated seed and fertilizer sales with other foreign delegations.
  • After the WHO removed Three Purities from its prequalified medicines list, Wei Kang withdrew its application and directed Zhang Chunming to pursue government cooperation, pharmacies, and aid organizations.
  • Zhang Chunming arranged for Sanqing medicines to be donated or sold at cost to secure the release of Zhu Shan and two other Chinese men held in Zhongfei Country.
Chapters 251–27525 summaries Read

Arc 12Sanqing’s Global Expansion

Wei Kang expanded Three Purities’ influence through charity, safer cardiovascular drugs, gene-editing technology, and acquisitions of abandoned drug formulas. After building a collection of more than two thousand formulas, he used the system’s drawing function and won a silver prize containing an electronic-product blueprint.

  • Taji exposed a Nairobi charity clinic that distributed expired medicines, and the resulting scandal boosted Three Purities as Kenyan authorities shut clinics and turned toward Chinese medical aid.
  • Wei Kang established an overseas foundation, appointed Sheng Changya and Zhang Chunming to lead its work, and launched Three Purities’ new cardiovascular drugs.
  • Old Man Liang switched from Irbesartan to Sanqing’s antihypertensive drug, while patients and netizens challenged Sanofi’s refusal to recall contaminated medicine in China.
  • Director Li ordered Sanofi to recall affected Irbesartan batches, apologize, and compensate patients after tests found nitrosamines, and Three Purities’ drug filled the market gap.
  • Sanqing reported more than $40 billion in annual revenue, rewarded its employees, entered Fortune’s Global 500, and Wei Kang became known as the Medicine King.
  • Wei Kang announced licensing terms for Sanqing’s fourth-generation gene-editing technology, and Pfizer’s Dr. Duke used samples to make major progress on Hemophilia A research.
  • Wei Kang acquired abandoned drug formulas from Pfizer and other pharmaceutical companies after rejecting Weicai’s demand for a share of future projects, then reached a preliminary licensing deal with Takeda Kazuhisa involving roughly five hundred formulas.
  • After asking Anmei to sort more than two thousand abandoned prescriptions, Wei Kang spent nearly a hundred thousand points on system draws and won a silver prize containing an electronic-product blueprint.
Chapters 276–30025 summaries Read
Volume 3 of 7
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS